Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with norwalk virus

Clinical and Vaccine Immunology

Volumn 19, Issue 2, 2012, Pages 284-287

  Czakó, Rita ^a   Atmar, Robert L ^a   Opekun, Antone R ^a   Gilger, Mark A ^a   Graham, David Y ^a   Estesa, Mary K ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; HISTO BLOOD GROUP ANTIGEN; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; EXPERIMENTAL INFECTION; HEMAGGLUTINATION INHIBITION TEST; HISTO BLOOD GROUP ANTIGEN BLOCKING ASSAY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; NOROVIRUS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; VIRAL GASTROENTERITIS;

ANTIBODIES, VIRAL; GASTROENTERITIS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTINATION, VIRAL; HUMANS; NORWALK VIRUS;

EID: 84856463423     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05592-11     Document Type: Article

References (17)

1. Atmar RL, et al. 2008. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14:1553-1557.
2. Atmar RL, et al. 2011. Norovirus vaccine protects against experimental human Norwalk virus illness. N. Engl. J. Med. 365:2178-2187.
3. El-Kamary SS, et al. 2010. Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202:1649-1658.
4. Glass RI, Parashar UD, Estes MK. 2009. Norovirus gastroenteritis. N. Engl. J. Med. 361:1776-1785.
5. Hakomori S. 1999. Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim. Biophys. Acta 1473:247-266.
6. Huang P, et al. 2005. Norovirus and histo-blood group antigens: demonstration of a wide spectrum of strain specificities and classification of two major binding groups among multiple binding patterns. J. Virol. 79:6714-6722. (Pubitemid 40677302)
7. Hutson AM, Atmar RL, Marcus DM, Estes MK. 2003. Norwalk viruslike particle hemagglutination by binding to H histo-blood group antigens. J. Virol. 77:405-415. (Pubitemid 36004980)
8. Hutson AM, Airaud F, LePendu J, Estes MK, Atmar RL. 2005. Norwalk virus infection associates with secretor status genotyped from sera. J. Med. Virol. 77:116-120. (Pubitemid 41076487)
9. Jiang X, Wang M, Graham DY, Estes MK. 1992. Expression selfassembly, and antigenicity of the Norwalk virus capsid protein. J. Virol. 66:6527-6532.
10. Kavanagh O, et al. 2011. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin. Vaccine Immunol. 18:1187-1190.
11. Lindesmith LC, et al. 2003. Human susceptibility and resistance to Norwalk virus infection. Nat. Med. 9:548-553.
12. Lindesmith LC, et al. 2010. Heterotypic humoral and cellular immune responses following Norwalk virus infection. J. Virol. 84:1800-1815.
13. Marionneau S, et al. 2002. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122:1967-1977. (Pubitemid 34651439)
14. Reeck A, et al. 2010. Serological correlate of protection against norovirus-induced gastroenteritis. J. Infect. Dis. 202:1212-1218.
15. Scallan E, et al. 2011. Foodborne illness acquired in the United States - major pathogens. Emerg. Infect. Dis. 17:7-15.
16. Tan M, et al. 2008. Outbreak studies of a GII-3 and a GII-4 norovirus revealed an association between HBGA phenotypes and viral infection. J. Med. Virol. 80:1296-1301. (Pubitemid 351706011)
17. Thorven M, et al. 2005. A homozygous nonsense mutation (428G→A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J. Virol. 79:15351-15355. (Pubitemid 43032317)